Afatinib Plus Nimotuzumb for NSCLC
NCT01861223
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class
Conditions
NSCLC
Interventions
DRUG:
afatinib (30 or 40mg) + nimotuzumab (100 or 200mg)
Sponsor
Samsung Medical Center